Regeneron (REGN)

Executive Summary

Regeneron Pharmaceuticals is a leading biotechnology company with a strong track record in discovering and commercializing innovative medicines. Its core portfolio includes blockbuster drugs such as Eylea (aflibercept) for retinal diseases, Dupixent (dupilumab) for allergic and inflammatory conditions, and Libtayo (cemiplimab) for oncology. Recent approvals, including high-dose Eylea (Eylea HD) and Dupixent for chronic obstructive pulmonary disease (COPD), have reinforced its growth trajectory. The company's proprietary VelociSuite technologies enable efficient antibody discovery and bispecific antibody development. Regeneron's pipeline features promising assets in gene therapy, oncology, and rare diseases, with several programs in late-stage development. Financially robust, the company is well-positioned to sustain R&D investment and pursue strategic collaborations. While facing competition in the anti-VEGF space and biosimilar threats to Eylea, Regeneron's diversified portfolio and deep pipeline provide resilience. The company's strong commercial execution and upcoming catalysts support a positive outlook.

Upcoming Catalysts (preview)

• H2 2026FDA decision on Dupixent for bullous pemphigoid85% success
• Q3 2026Phase 3 readout for Eylea HD in diabetic retinopathy70% success
• Q2 2026BLA resubmission for odronextamab in R/R follicular lymphoma60% success